[Management of CAR-T cell-related encephalopathy syndrome in adult and pediatric patients: Recommendations of the French Society of Bone Marrow transplantation and cellular Therapy (SFGM-TC)].
Prise en charge pratique d’une encéphalopathie liée au traitement par cellules CAR-T chez l’adulte et l’enfant : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC).
Adrenal Cortex Hormones
/ therapeutic use
Adult
Anticonvulsants
/ therapeutic use
Child
Cytokine Release Syndrome
/ etiology
Disease Management
Humans
Immunotherapy, Adoptive
/ adverse effects
Incidence
Neuroimaging
Neurotoxicity Syndromes
/ diagnosis
Risk Factors
Salvage Therapy
Severity of Illness Index
Syndrome
CAR-T
CRES
Management
Neurologic disorders
Troubles neurologiques
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
22
02
2019
revised:
06
05
2019
accepted:
10
05
2019
pubmed:
17
6
2019
medline:
4
3
2020
entrez:
17
6
2019
Statut:
ppublish
Résumé
CAR-T cell-related encephalopathy syndrome (CRES) reflects the potential neurotoxicity of this therapeutic approach and must be considered in the presence of any neurological symptom after the infusion of the CAR-T. This is the second most common adverse event under this therapy and its incidence varies between 12 and 55%. The median time of the onset of the first neurologic symptoms is 4days after CAR-T infusion. The duration of CRES symptoms is generally between 2 and 4days, but late CRES may occur. Monitoring and diagnosis of CERS includes clinical exam, magnetic resonance imaging and electroencephalography. In addition to symptomatic treatments, corticosteroids represent the cornerstone of the high-grade CERS treatment. Drugs targeting IL-6 should be restricted to severe forms, especially those associated with cytokine release syndrome. The purpose of this workshop is to provide practical help in dealing with this complication.
Identifiants
pubmed: 31202556
pii: S0007-4551(19)30224-3
doi: 10.1016/j.bulcan.2019.05.001
pii:
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Anticonvulsants
0
Types de publication
Consensus Development Conference
Journal Article
Practice Guideline
Langues
fre
Sous-ensembles de citation
IM
Pagination
S12-S17Informations de copyright
Copyright © 2019 Société Française du Cancer. All rights reserved.